Professor Michael Horowitz: Ledger

Stories naming Professor Michael Horowitz. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Role	Organisation	Sources
Professor	Centre of Research Excellence in Translating Nutritional Science to Good Health	Brandon BioCatalyst portfolio (Tue 3 Aug 2021), Brandon Capital portfolio (Tue 3 Aug 2021), Brandon Capital portfolio (Fri 12 Jun 2020), Brandon Capital portfolio (Fri 12 Jun 2020), Brandon BioCatalyst portfolio (Fri 12 Jun 2020)
Founder	Glyscend, Inc.	Brandon BioCatalyst portfolio (Wed 29 Sep 2021), Brandon BioCatalyst portfolio (Tue 3 Aug 2021)
	Glyscend	Brandon Capital portfolio, Brandon BioCatalyst portfolio

Series A $29m

Glyscend Therapeutics commences South Australia Phase I clinical trial to progress new type 2 diabetes treatment

Glyscend Therapeutics, a Johns Hopkins spin-out, is starting a Phase I trial of its type 2 diabetes pill in Adelaide; the piece recalls its AUD$29 million Series A led by Brandon Capital's MRCF.

Also Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio

Professor Michael Horowitz

Roles

Coverage

Glyscend Therapeutics commences South Australia Phase I clinical trial to progress new type 2 diabetes treatment

Innovative type two diabetes treatment scores $29m